Introduction
The field of cardiology has witnessed remarkable advancements over the years, with novel technologies continually reshaping the landscape of cardiovascular care. Among these innovations, drug-coated balloons (DCBs) have emerged as a promising intervention, offering a unique approach to tackling coronary artery diseases. This article briefly explains drug-coated balloons, how they work, their clinical applications, and their advantages over other stents.
What Is a Drug-Coated Balloon (DCB)?
Drug-coated balloon (DCB) is an innovative device for percutaneous coronary intervention (PCI), which has demonstrated favorable outcomes in comparison to traditional drug-eluting stents (DES) due to its ability to deliver an anti-restenotic drug rapidly locally without the use of durable polymer or metal stent. The concept of DCB depends on the fast release of the drug and the rapid healing of the vessel wall and also, achieving a sustained effect in the first hours to days post angioplasty. DCB effectively inhibits restenosis and is designed to have the same anti-restenotic effects as drug-eluting stent (DES) with added flexibility and leaving nothing in the blood vessel.
DCB is a semi-compliant angioplasty balloon coated with an antiproliferative agent, typically Paclitaxel. that can exert anti-restenotic efficacy by permeating the blood vessel wall upon balloon contact, unlike the long-term drug release of DES, which releases drugs over an extended period. DCB transiently releases the drug within a remarkably short time frame of 30 to 60 seconds.
Currently, DES is regarded as the most appropriate therapy for coronary lesions. DES, however, has certain device-related issues and flaws that have only been partially addressed by more recent generations and brands.
How Does a Drug-Coated Balloon (DCB) Work?
Drug-coated balloons operate on a simple yet effective principle. They are angioplasty balloons coated with an antiproliferative drug, typically Paclitaxel, with a dose between 2 and 3.5 μg/mm2 on the balloon surface. The balloon is inflated at the site of the coronary artery stenosis or lesion, delivering the drug directly to the vessel wall. This localized drug delivery helps to inhibit the excessive proliferation of smooth muscle cells, preventing restenosis, a common issue seen in conventional angioplasty and bare-metal stents.
When Is a Drug-Coated Balloon (DCB) Used?
DCB is commonly used to treat the following conditions:
-
Treatment of Coronary In-Stent Restenosis (ISR): DCBs have demonstrated superior outcomes in the treatment of coronary ISR compared to plain-old balloon angioplasty.
-
Coronary Small Vessel Disease: Small vessel disease poses a significant challenge in coronary interventions. DCBs, as seen in some studies, have exhibited efficacy in reducing late lumen loss and binary restenosis rates, making them a valuable option for treating lesions in small vessels.
-
Coronary Bifurcation Disease: Coronary bifurcation lesions require precise intervention strategies. In clinical trials DCBs show promise in managing bifurcation lesions.
-
Diabetic Patients: Diabetes affects over 25 percent of patients who are referred for coronary revascularization procedures tend to be at high risk for cardiovascular disease and show poor results post-PCI, with higher rates of in-stent restenosis (ISR), stent thrombosis, myocardial infarction, and death. Notably, diabetic patients referred for coronary revascularization procedures face unique challenges, as diabetes contributes to more complex, diffuse, and long lesions in smaller caliber vessels. DCBs may be a better option than DES(Drug-eluting stents) in these kinds of lesions because they are not as prone to cracks and uneven coating distribution as DES are, which can cause ISR, inflammation, and platelet aggregation stent thrombosis.
-
High Bleeding Risk Patients: The rising number of percutaneous coronary intervention (PCI) procedures in elderly patients and those on oral anticoagulation because of atrial fibrillation are at high bleeding complications in the first year after the procedure. Bleeding after PCI significantly increases mortality and results in other adverse outcomes such as nonfatal myocardial infarction, and prolonged hospital stay, so it should therefore be avoided. Traditional stents used in PCI require dual antiplatelet therapy (DAPT) to prevent blood clots, but this increases the risk of bleeding. DCBs offer advantages over stent implantation in patients at high bleeding risk. Unlike stents, DCBs are temporary and do not require permanent implantation. The recommended duration of DAPT is 4 weeks after a DCB. This shortened dependency on DAPT significantly reduces bleeding risk compared to stents.
-
Acute Coronary Syndromes: Acute Coronary Syndromes (ACS), a potentially life-threatening condition triggered by blocked or narrowed coronary arteries, the use of DCBs is still evolving. Although stents remain the most common intervention, DCBs offer a promising alternative in specific situations.
What Are the Advantages of a Drug-coated Balloon (DCB) Over Other Stents?
The following are the advantages of DCB over other stents:
-
Reduced Risk of Stent Thrombosis: DCBs, being temporary and not permanent implants, eliminate the risk of stent thrombosis.
-
Improved Vessel Healing: The drug released by DCBs promotes better healing of the vessel wall, reducing the risk of restenosis.
-
No Long-Term Foreign Body: Unlike permanent stents, DCBs are removed after the procedure, leaving no foreign body behind, and minimizing long-term complications.
-
Greater Flexibility: DCBs can treat a wider range of lesions, including small vessels and bifurcations, offering increased procedural flexibility.
-
Uniform Drug Distribution: DCBs ensure uniform drug distribution on the vessel wall, enhancing their effectiveness.
-
Quick and Transient Drug Elution: DCBs transiently release the drug within a short time frame, promoting efficient drug delivery.
-
Control Over Drug Release: The controlled release of the total drug dose is a notable feature, providing a tailored approach to treatment.
-
Avoidance of Polymeric Matrix: Unlike DES, DCBs do not utilize a polymeric matrix, reducing the risk of complications associated with these materials.
-
Reduction in Dual Antiplatelet Therapy (DAPT): DCBs require a shorter duration of DAPT, significantly reducing the risk of bleeding compared to stents.
Conclusion
Drug-coated balloons have emerged as a valuable tool in the armamentarium of interventional cardiologists, offering a novel approach to address the limitations of traditional angioplasty and stenting. While challenges exist, ongoing research and technological advancements hold the promise of further improving the safety and efficacy of this innovative therapy. As the field continues to evolve, drug-coated balloons are likely to play an increasingly significant role in shaping the future of cardiovascular interventions.
